SCHEMBL7968066

SCHEMBL7968066

Cc1ccc(-c2nc3c(o2)C(=O)c2ccccc2C3=O)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP1 O94782 4/20 0.77
USP19 O94966 2/20 0.77
WDR48 Q8TAF3 1/20 0.77
UCHL3 P15374 1/20 0.74
USP2 O75604 2/20 0.62
USP8 P40818 2/20 0.62
OTUB1 Q96FW1 2/20 0.62
USP36 Q9P275 1/20 0.62
RAB9A P51151 8/20 0.49
NPC1 O15118 7/20 0.49
TSHR P16473 3/20 0.46
MAPK1 P28482 2/20 0.46
HPGDS O60760 1/20 0.46
TP53 P04637 1/20 0.46
PKM P14618 1/20 0.46
AGTR1 P30556 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.44
HPGD P15428 5/20 0.44
MAPT P10636 4/20 0.44
ALDH1A1 P00352 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29629184 0.87 USP1 (1.00) USP1USP19WDR48UCHL3USP2
SCHEMBL29629183 0.87 USP1 (1.00) USP1USP19WDR48UCHL3USP2
SCHEMBL7808226 0.87 USP1 (1.00) USP1USP19WDR48UCHL3USP2
SCHEMBL31276578 0.85 USP1 (1.00) USP1USP19WDR48UCHL3USP2
SCHEMBL7815859 0.85 USP1 (1.00) USP1USP19WDR48UCHL3USP2
SCHEMBL19225117 0.85 USP1 (0.77) USP1USP19WDR48UCHL3USP2
SCHEMBL7808410 0.85 USP1 (0.77) USP1USP19WDR48UCHL3USP2
SCHEMBL19220486 0.84 USP1 (0.82) USP1USP19WDR48UCHL3USP2
SCHEMBL7808315 0.84 USP1 (0.71) USP1USP19WDR48UCHL3USP2
SCHEMBL7812967 0.84 USP1 (0.71) USP1USP19WDR48UCHL3USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725425-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-08-08 US disclosed
US-9725425-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-08-08 US disclosed
US-20170202810-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-07-20 US disclosed
US-9518032-B2 Small molecule inhibitors of USP1 deubiquitinating enzyme activity DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-13 US disclosed
US-20130253005-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-09-26 US disclosed
US-6262095-B1 TREATMENT OF ILLNESS ASSOCIATED WITH AN ALTERATION IN VENOUS FUNCTION AND/OR INFLAMMATORY EDEMA LABORATOIRE INNOTHERA (FR) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130253005-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY USP1, USP2, USP28 USP1 1/4885USP19 20/4885WDR48 483/4885
US-20170202810-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY USP1, USP2, USP28 USP1 1/4885USP19 20/4885WDR48 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.